HomeNewsTrendsHealthCOVID-19 vaccine for 12-14-year-olds to start from March 16; all above 60 years can take boosters

COVID-19 vaccine for 12-14-year-olds to start from March 16; all above 60 years can take boosters

The new decision will mean that, while Corbevax will be offered to the younger adolescents, those in the 15-17-year age group will continue to get Covaxin.

March 14, 2022 / 14:46 IST
Story continues below Advertisement
Representative image: Reuters
Representative image: Reuters

More than two months after opening COVID-19 vaccination for the 15-17-year age group in the country, the Centre has now announced plans to expand the programme further to include the 12-14-year age group, beginning March 16. The estimated population of this age group in India is 7.11 crore, said government sources.

The younger adolescents will be offered Corbevax by Hyderabad based Biological E, a receptor binding domain protein sub unit vaccine, developed in collaboration with the USA’s Baylor College.

Story continues below Advertisement

This vaccine, to be administered in two doses given 28 days apart, was granted the emergency use authorization by the Drug Controller General of India for use in 12-plus population groups in December last year.

The health ministry said that the decision has been taken following “due deliberations with scientific bodies”.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show